Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Plays Up Biotech But Major Pipeline Developments Are Long-Term

Executive Summary

Eli Lilly's biotech strategy calls for the creation of a pipeline that will yield one new biotechnology-based drug launch each year beginning in 2011, the company announced
Advertisement

Related Content

Lilly Gets Ready To Compete With Its Late-Stage Diabetes Pipeline
Shareholder Activism As Public Venture Capital? In Some Cases, It’s Icahn’s Approach
Lilly’s Legal Division Steers Firm Through Rough Seas Of Civil, Patent Cases
Lilly’s Legal Division Steers Firm Through Rough Seas Of Civil, Patent Cases
Merck's Head-long Leap into Follow-On Biologics
Prasugrel Delay Could Extend Well Into 2009; FDA Eyes February Cmte. Review
Prasugrel Delay Could Extend Well Into 2009; FDA Eyes February Cmte. Review
Lilly’s ImClone Buy Adds Oncology Candidates And Pipeline Pressures
Advertisement
UsernamePublicRestriction

Register

PS050446

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel